Category: Therapeutics

Cell Therapy Manufacturing: The USD 8 Billion+ Growth Opportunity

Cell-based therapies have gained significant attention in the overall biopharmaceutical industry. The personalized nature of these treatment options render them highly specific and, according to a number of clinical studies, safe and efficacious. Around 20 such therapies have been approved so far; recent approvals include Alofisel® (2018), YESCARTA® (2017) and Kymriah® (2017). It is also

The Growing Importance of Oral Proteins and Peptides

Protein and peptide-based therapeutics have been in use for more than three decades since the approval of recombinant human insulin, the first protein therapy, in 1982. Earlier, most biologic drugs were delivered through the subcutaneous route. However, over time, advances in delivery formulations have enabled the development of orally administrable versions of therapeutic proteins /

Pharmaceutical Contract Manufacturing: Current Market Landscape and Future Opportunities

 The present pipeline of pharmaceutical products is becoming increasingly complex and requires specialized facilities, equipment and operational expertise. In addition, the costs associated with acquiring manufacturing capabilities are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. Over the years, the contract manufacturing market has grown

Gene Therapies: Mapping the Future Growth Potential

The first gene therapy, Gendicine®, was only approved in 2003 in China; since then, the domain has evolved significantly. The ‘Gene Therapy Market (2nd Edition), 2018-2030’ report provides an extensive study on the current market landscape of gene therapies, with a prime focus on gene augmentation based therapies and oncolytic viral therapies, featuring an elaborate discussion on the

Novel Drugs and Smart Devices for Respiratory Disorders: Mapping the Future Potential

The World Health Organization (WHO) estimates the global prevalence of two of the most common chronic respiratory diseases, namely asthma and chronic obstructive pulmonary disease (COPD), to be around 335 million and 400 million patients respectively. According to the data provided by the WHO, more than 3 million people die annually from COPD. Asthma, on

Antibody Drug Conjugates: Riding on the Second Growth Wave

While there are close to 200 ADCs in various stages of development, the market field is currently going through a gradual transition, shifting from relying on conventional technologies to newer approaches for generating ADCs. The ‘Antibody Drug Conjugates Market (4th Edition), 2017-2030’ report provides a comprehensive study on the current landscape of ADCs, featuring an elaborate discussion

Microbiome Therapeutics and Diagnostics: Unlocking the Future Potential

Microbiome therapeutics represent a new frontier in the field of medicine. Currently, there are many probiotics, prebiotics, and medical foods and supplements that are commercially available, and several drug / therapy candidates that claim to be capable of modifying / manipulating the microbiome in order to provide therapeutic benefits. The ‘Microbiome Therapeutics and Diagnostics Market (2nd Edition), 2017-2030’ report provides a